Fulgent Genetics vs Grail
FLGT and GRAL side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How FLGT and GRAL compare
Grail is the larger company, worth 7.1 times as much as Fulgent Genetics ($4.7B against $666M).
Grail grew revenue faster over the last twelve months (23.1% versus 6.8% for Fulgent Genetics).
Fulgent Genetics keeps more of each dollar of sales as profit, with a net margin of −26.0% compared with −237% at Grail.
Grail scores higher on the StockData Score (10 against 7 for Fulgent Genetics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | FLGT | GRAL |
|---|---|---|
| Size and price | ||
| Market cap | $666M | $4.7B |
| Share price | $24.21 | $105.88 |
| Change, 1 year | −16.8% | 33.0% |
| Change, 5 years | −75.2% | – |
| Beta (5Y) | 0.49 | 2.06 |
| Employees | 1,300 | 910 |
| StockData Score | ||
| Total score | 7 | 10 (better) |
| Valuation score | 3 (better) | 1 |
| Growth score | 0 | 2 (better) |
| Performance score | 1 | 1 |
| Health score | 3 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.1× (better) | 28.6× |
| P/B | 0.7× (better) | 1.9× |
| FCF yield | −15.6% | −6.3% (better) |
| Fair value | $45.28 | – |
| Margin of safety | 46.5% | – |
| Growth | ||
| Revenue growth (TTM) | 6.8% | 23.1% (better) |
| Revenue growth, 5Y average | −5.2% | – |
| Profitability | ||
| Gross margin | 35.6% | – |
| Operating margin | −37.7% (better) | −338% |
| Net margin | −26.0% (better) | −237% |
| FCF margin | −32.0% (better) | −179% |
| Return on equity | −8.0% (better) | −16.1% |
| Return on invested capital | −10.9% (better) | −26.0% |
| Financial health | ||
| Debt / equity | 0.00 (better) | 0.00 |
| Interest coverage | −1019.0× | – |
| Current ratio | 6.34 | 10.95 (better) |
| Altman Z-score | 5.25 (better) | 4.06 |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Buyback yield | 9.6% | – |
| Shareholder yield | 9.6% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 57.0% | 87.6% |
| Held by insiders | 39.5% | 11.0% |
| Insider net buying, 12 months | −$286K (better) | −$38.3M |
| Short interest, % of float | 12.1% | 20.1% |
Go deeper
- FLGT stock overview
- FLGT income statement
- FLGT valuation and score
- GRAL stock overview
- GRAL income statement
- GRAL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.